PRODUCTION AND CHARACTERIZATION OF RECOMBINANT PROTEINS CONTAINING BET V 2 ANTIGENIC EPITOPES OF BETULA PENDULA



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim of investigation. Production of immunologically active recombinant protein of Bet v 2 allergen ofbirch pollen. Materials and methods. mRNA was isolated from a sample ofbirch pollen. cDNA library was derived using SMART technology. Gene Bet v 2 was amplified by means of PCR with primers from the cDNA. The resulting PCR fragment of the gene was cloned into the vector pET29b(+). The recombinant protein Bet v 2 was expressed in cells E. coli, transformed with a plasmid. The recombinant protein was purified using NiNTA agarose. Immunological activity of the recombinant protein Bet v 2 was measured by ELISA and immunoblot methods. Results. The production system of the recombinant allergen Bet v 2 preparation suitable for immunological tests was developed during the research project. In the first phase allergen Bet v 2 gene was cloned from birch pollen collected in Russia. The gene was inserted into the vector pET29(+) for expression in bacterial cells. The expression cell strain E. coli was obtained with this plasmid. The synthesis of the recombinant protein that accumulates in inclusion bodies was activated in bacterial cells. The procedure of recombinant protein Bet v 2 isolation from inclusion bodies was developed by one round of chromatography purification. The recombinant protein isolation was carried out by chromatography on Niagarose. The highly purified preparation of the recombinant allergen was obtained as a result. The recognition of the recombinant protein Bet v 2 by sera varied in ELISA, indicating a different degree of patients sensitization to this allergen. In the immunoblot test the preparation was active only in 15% of cases. Apparently, reactive epitopes of the allergen are mainly conformational ones and are active in ELISA test, whereas linear epitopes, that are active in immunoblot, are in the minority. Conclusion.The system for production of recombinant allergen Bet v 2 preparation suitable for immunological tests has been developed.

Full Text

Restricted Access

About the authors

A V Chernysheva

Institute of Immunology

V V Tyutyaeva

Federal State Budget Institution of Science Engelhardt Institute of Molecular Biology, Russian Academy of Sciences

A V Pivovarova

Federal State Budget Institution of Science Engelhardt Institute of Molecular Biology, Russian Academy of Sciences

I V Andreev

Institute of Immunology

M N Sankov

Institute of Immunology

Y V Kuzmenko

Federal State Budget Institution of Science Engelhardt Institute of Molecular Biology, Russian Academy of Sciences

E S Starodubova

Federal State Budget Institution of Science Engelhardt Institute of Molecular Biology, Russian Academy of Sciences

A I Martynov

Institute of Immunology

Email: medimm@mail.ru

V L Karpov

Federal State Budget Institution of Science Engelhardt Institute of Molecular Biology, Russian Academy of Sciences

References

  1. Казиев А.Х., Райкис Б.Н., Пожарская В.О. Перспективы разработки рекомбинантных аллергенов. Аллергология. 2002, т. 2, с. 17-20.
  2. Erler A., Hawranek Т., Krückemeier L. et al. Proteomic profiling ofbirch (Betula verrucosa) pollen extracts from different origins. Proteomics. 2011, v. 11 (8), p. 1486-1498.
  3. Cromwell O., Häfner D., Nandy A. Recombinant allergens for specific immunotherapy. J. Allergy Clin. Immunol. 2011, v. 127 (4), p. 865-872.
  4. Schmidt W.M., Mueller M.W. CapSelect: a highly sensitive method for 5’ CAP-dependent enrichment of full length cDNA in PCR-mediated analyses of mRNAs. Nucleic Acid Res. 1999, v. 27, p. 31.
  5. Zhu Y.Y., Machleder E.M., Chenchik A. et al. Reverse transcriptase template switching: a SMART approach for full-length cDNA library construction. Biotechniques. 2001, v. 30, p. 892-897.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright © Pharmarus Print Media, 2012



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies